PENTOXIL |
TRENTAL |
OXPENTIFYLLINE |
C04AD03 |
BL-191 |
PENTOXIFYLLINE |
NEOTREN MR |
TRENTAL 100 |
NSC-637086 |
TRENTAL 400 |
PENTOXIFILINA |
PENTOXIFYLLIN |
TRENTAL® |
PENTOXIFYLLINUM |
chemidplus:6493-05-6 |
pubchem.compound:4740 |
drugbank:00806 |
rxcui:8013 |
chembl:CHEMBL628 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | for treatment of amyotrophic lateral sclerosis (ALS) |
Year of Approval | 1984 |
Drug Class | hemorrheologic agents |
Drug Class | platelet aggregation inhibitors |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
Trial Name | pentoxifylline, EHT0201 |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Adenosine A2 receptor antagonist |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Adenosine A2 receptor antagonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
PENTOXIFYLLINE | Primary Drug Name |
Drug Class | platelet aggregation inhibitors |
Drug Class | hemorrheologic agents |
Year of Approval | 1984 |
Drug Indications | for treatment of amyotrophic lateral sclerosis (ALS) |
Drug Class | Small Molecule |
FDA Approval | approved |
C733 | NCI drug code |
D09QEI | TTD Drug ID |